Correction to :: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt; Kim A. Papp; Christopher E. M. Griffiths; Lluís Puig Sanz; Jamie Weisman; Yves Dutronc; Lisa Farmer Kerr; Dapo Ilo; Lotus Mallbris; Matthias Augustin

doi:10.1007/s40257-018-0353-x

Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

Andrew Blauvelt, Kim A. Papp, Christopher E. M. Griffiths, Lluís Puig Sanz, Jamie Weisman, Yves Dutronc, Lisa Farmer Kerr, Dapo Ilo, Lotus Mallbris, Matthias Augustin

Departament de Medicina

Lancaster University and Whitworth Gallery, Manchester, UK

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

3 Cites (Scopus)

Idioma original	Anglès
Pàgines (de-a)	457-457
Nombre de pàgines	1
Revista	American Journal of Clinical Dermatology
Volum	19
DOIs	https://doi.org/10.1007/s40257-018-0353-x
Estat de la publicació	Publicada - 2018

Accés al document

10.1007/s40257-018-0353-x

https://ddd.uab.cat/record/190768

Com citar-ho

Blauvelt, A., Papp, K. A., Griffiths, C. E. M., Puig Sanz, L., Weisman, J., Dutronc, Y., Kerr, L. F., Ilo, D., Mallbris, L., & Augustin, M. (2018). Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American Journal of Clinical Dermatology, 19, 457-457. https://doi.org/10.1007/s40257-018-0353-x

@article{ab48b92d68db4ee78bbd174fac810912,

title = "Correction to :: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)",

author = "Andrew Blauvelt and Papp, {Kim A.} and Griffiths, {Christopher E. M.} and {Puig Sanz}, Llu{\'i}s and Jamie Weisman and Yves Dutronc and Kerr, {Lisa Farmer} and Dapo Ilo and Lotus Mallbris and Matthias Augustin",

year = "2018",

doi = "10.1007/s40257-018-0353-x",

language = "English",

volume = "19",

pages = "457--457",

}

Blauvelt, A, Papp, KA, Griffiths, CEM, Puig Sanz, L, Weisman, J, Dutronc, Y, Kerr, LF, Ilo, D, Mallbris, L & Augustin, M 2018, 'Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)', American Journal of Clinical Dermatology, vol. 19, pàg. 457-457. https://doi.org/10.1007/s40257-018-0353-x

Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). / Blauvelt, Andrew; Papp, Kim A.; Griffiths, Christopher E. M. et al.
In: American Journal of Clinical Dermatology, Vol. 19, 2018, pàg. 457-457.

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

TY - JOUR

T1 - Correction to :

T2 - Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)

AU - Blauvelt, Andrew

AU - Papp, Kim A.

AU - Griffiths, Christopher E. M.

AU - Puig Sanz, Lluís

AU - Weisman, Jamie

AU - Dutronc, Yves

AU - Kerr, Lisa Farmer

AU - Ilo, Dapo

AU - Mallbris, Lotus

AU - Augustin, Matthias

PY - 2018

Y1 - 2018

U2 - 10.1007/s40257-018-0353-x

DO - 10.1007/s40257-018-0353-x

M3 - Article

C2 - 29600394

SN - 1179-1888

VL - 19

SP - 457

EP - 457

JO - American Journal of Clinical Dermatology

JF - American Journal of Clinical Dermatology

ER -

Blauvelt A, Papp KA, Griffiths CEM, Puig Sanz L, Weisman J, Dutronc Y et al. Correction to : Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3). American Journal of Clinical Dermatology. 2018;19:457-457. doi: 10.1007/s40257-018-0353-x